-
1.
公开(公告)号:US20140170147A1
公开(公告)日:2014-06-19
申请号:US14178892
申请日:2014-02-12
申请人: Janine R. SHULOK , Feng CONG , Mark C. FISHMAN , Seth ETTENBERG , Michael BARDROFF , Mariel DONZEAU , Stefanie URLINGER
发明人: Janine R. SHULOK , Feng CONG , Mark C. FISHMAN , Seth ETTENBERG , Michael BARDROFF , Mariel DONZEAU , Stefanie URLINGER
IPC分类号: C07K16/22 , A61K31/675 , A61K39/395
CPC分类号: C07K16/22 , A61K31/675 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.
摘要翻译: 提供了与蛋白质靶标Dickkopf(DKK1)结合的抗体和片段,以及用于治疗靶细胞,特别是与溶骨性病症相关的细胞的使用方法和试剂盒。
-
公开(公告)号:US20140341901A1
公开(公告)日:2014-11-20
申请号:US14163230
申请日:2014-01-24
申请人: Janine R. SHULOK , Feng CONG , Mark C. FISHMAN , Seth ETTENBERG , Michael BARDROFF , Mariel DONZEAU , Stefanie URLINGER
发明人: Janine R. SHULOK , Feng CONG , Mark C. FISHMAN , Seth ETTENBERG , Michael BARDROFF , Mariel DONZEAU , Stefanie URLINGER
IPC分类号: C07K16/22 , A61K45/06 , A61K31/675 , A61K39/395
CPC分类号: C07K16/22 , A61K31/675 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.
-
公开(公告)号:US20180066067A1
公开(公告)日:2018-03-08
申请号:US15073156
申请日:2016-03-17
申请人: Feng CONG , Huaixiang HAO , Lloyd B. KLICKSTEIN , Rou-Fun KWONG , Ann TAYLOR , Yang XIE
发明人: Feng CONG , Huaixiang HAO , Lloyd B. KLICKSTEIN , Rou-Fun KWONG , Ann TAYLOR , Yang XIE
CPC分类号: C07K16/40 , A61K31/40 , A61K38/53 , A61K39/3955 , A61K45/06 , C12N9/93 , C12Y603/02019 , A61K2300/00
摘要: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of β-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
-
公开(公告)号:US20160176956A1
公开(公告)日:2016-06-23
申请号:US14974318
申请日:2015-12-18
申请人: Feng CONG , William DIETRICH , Nathalie GEORGE , Dong LIU , Asher SCHACHTER , Aditi SONI , Jing ZHOU
发明人: Feng CONG , William DIETRICH , Nathalie GEORGE , Dong LIU , Asher SCHACHTER , Aditi SONI , Jing ZHOU
IPC分类号: C07K16/22 , A61K38/18 , A61K39/395 , A61K47/48
CPC分类号: C07K16/22 , A61K38/1816 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/76 , C07K2317/90 , C07K2317/92
摘要: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.
摘要翻译: 本发明涉及抗体及其与人BMP6的抗原结合片段及其组合物及其使用方法。
-
-
-